Immune and viral therapies for malignant primary brain tumors

Area of Science:

• Neuro-oncology
• Immunotherapy
• Virology

Background:

• Glioblastoma multiforme (GBM) is a highly lethal primary brain tumor.
• Current treatments (surgery, radiation, chemotherapy) are insufficient for a cure.
• Biological therapies offer new hope for brain tumor treatment.

Purpose of the Study:

• To review current advancements in immune and viral-based therapies for glioblastoma.
• To explore novel strategies for stimulating anti-tumor immune responses in the brain.
• To discuss the potential of these therapies to augment existing treatment protocols.

Main Methods:

• Review of peripheral activation of antigen-presenting cells (e.g., dendritic cells) to stimulate T cells.
• Ex vivo expansion and transfer of immune cells (dendritic cells, T cells, CAR-T cells).
• Gene therapy using viral vectors for cytokine expression and oncolytic virotherapy.

Main Results:

• Immune cell-based strategies aim to enhance T cell recognition and destruction of tumor cells.
• Engineered T cells (CAR-T) and monoclonal antibodies target specific tumor antigens and immune checkpoints.
• Gene therapy and oncolytic viruses are explored for activating immune responses and directly destroying tumor cells.

Conclusions:

• Immune and viral therapies represent promising avenues for treating malignant brain tumors.
• These approaches have the potential to augment the current standard of care.
• Further preclinical and clinical studies are crucial to realizing the curative potential of these biological therapies.